Corium Inc.
  • Who We Are
    • About Us
    • Leadership
    • Board of Directors
    • Our Mission & Values
  • What We Do
    • Our Products & Pipeline
    • Partnering
    • Our Proprietary Platforms
  • News & Media
  • Join Us
  • Contact Us
  • Who We Are
    • About Us
    • Leadership
    • Board of Directors
    • Our Mission & Values
  • What We Do
    • Our Products & Pipeline
    • Partnering
    • Our Proprietary Platforms
  • News & Media
  • Join Us
  • Contact Us

Pipeline Test

Innovative Technologies Driving New Products

The foundation of our transdermal business was established through strong partnerships.

Corium has demonstrated a strong track record of developing complex transdermal products for partners and manufacturing them for clinical development and commercial sale. Today, we have built on this foundation to create a balanced business model, allowing us to build a high-value proprietary CNS pipeline while continuing to create value for existing and new partners.

Corium’s two lead proprietary product candidates are focused on the treatment of Alzheimer’s disease:

Proprietary Pipeline

PRODUCT APPLICATION STATUS
Corplex Donepezil Alzheimer’s Disease Pilot BE
Corplex Memantine Alzheimer’s Disease Phase 1
Corplex Ropinirole Parkinson’s Disease Preclinical
MicroCor hPTH(1-34) Osteoporosis Phase 2
MicroCor Zolmitriptan Acute Migraine Preclinical

Our partnered programs include commercial and development-stage transdermal product opportunities:

Partnered Pipeline

SPONSOR PRODUCT APPLICATION STATUS
Clonidine TDS Hypertension Marketed
Fentanyl TDS Pain Marketed
Crest® Whitestrips (5 Products) Teeth Whitening Marketed
Twirla® Contraception Phase 3
Undisclosed Motion Sickness ANDA Filed
Aripiprazole Schizophrenia Phase 1
  • Pipeline & Products
  • Partnering
  • Our Proprietary Platforms
  • Home
  • Who We Are
  • What We Do
  • News & Media
  • Join Us
  • Contact Us
  • Terms of Use
  • Privacy Policy








© 2020 Corium Inc. All rights reserved.